Cure SMA is pleased to announce the creation of a new chapter in northern New Jersey, serving families and supporters with zip codes starting with 07, 085, 086, 087, and 088. Led by chairpersons Kara Hartnett (family support), Anna Pham (fundraising), and Zainab Jaffar (communications), the chapter is excited to begin helping families throughout their […]
Cure SMA Welcomes the North Jersey Chapter Read More »
Cure SMA President Kenneth Hobby was a featured panelist at Partnering for Cures, a conference convened by the Milken Institute’s FasterCures initiative. At the event, over 700 research innovators—including senior government officials, patient advocates, scientists, major investors, industry CEOs and philanthropists—gathered to discuss some of the most common barriers to speeding up innovation in medical
Cytokinetics, in collaboration with Astellas, has announced further details about a planned Phase 2 clinical trial of CK-2127107 in patients with spinal muscular atrophy (SMA). CK-2127107 is a skeletal muscle activator. The drug has the potential to improve muscle function, either alone or in combination with other drugs. We are excited to see the continued
Cytokinetics Announces New Details on Upcoming Phase 2 Trial Read More »
Cure SMA, along with collaborators from Biogen and the SMA Foundation, have published a paper in the journal BMC Neurology. Over the past year, we’ve completed 16 focus group sessions and 37 interviews in the US with 96 participants including: 21 with individuals with SMA; 64 parents of individuals affected by SMA; and 11 clinicians
Cure SMA Publishes Journal Article on the Patient Voice Read More »
Cure SMA recently received a donation of 10 special tomato feeder seats from Jadon’s Hope Foundation. These were immediately sent out to families who were on a waiting list for a feeder seat. Thanks to Jadon’s Hope, these familes no longer have to wait! Jadon’s Hope Foundation was created by Tony and Kristin Burks in
Jadon’s Hope Foundation Donates 10 New Tomato Feeder Seats Read More »
Cure SMA-funded researchers Rebecca Hurst Davis and Kathy Swoboda have published a paper, “Responses to Fasting and Glucose Loading in a Cohort of Well Children with Spinal Muscular Atrophy Type II” in the journal Pediatrics. Elizabeth A. Miller and Ren Zhe Zhang also co-authored the paper. This study was funded by an initial $50,000 Cure
Cure SMA-Funded Researchers Publish Paper in Journal Pediatrics Read More »
Isis Pharmaceuticals, Inc. announced that it has initiated an open-label extension study, SHINE. The SHINE study provides ISIS-SMNRx to infants and children with spinal muscular atrophy (SMA) who have completed their participation in the Phase 3 ENDEAR and CHERISH studies and are eligible to participate in SHINE. All patients in the SHINE study will receive
Isis Pharmaceuticals Announces SHINE, an Open-Label Extension Study Read More »
On Monday, November 9, Cure SMA will be hosting a one-hour webinar on clinical trials and regulatory topics. The webinar will be held at 11:00am CST (9:00am PST/10:00am MST/12:00pm EST). Jill Jarecki, Research Director at Cure SMA, will be joined by a panel of three drug development experts to discuss clinical trial design, expanded access,
Cure SMA to Host Clinical and Regulatory Webinar Read More »
PTC Therapeutics, in partnership with Roche and the SMA Foundation, recently announced new results from their ongoing Phase 2 trial of RG7800, a small molecule splicing modifier for SMA. The presentation was made at last week’s World Muscle Congress in the United Kingdom. Results from the first cohort of patients enrolled in the Phase 2
PTC Announces New Clinical Trial Results at World Muscle Congress Read More »
Biogen and Isis Pharmaceuticals recently provided an update on the clinical development of ISIS-SMNRx, which is currently being tested in Phase 3 clinical trials: Dear members of the SMA community, Over the past few months, we have received many questions from members of the SMA community about ISIS-SMNRx and when it might be widely available
Community Update on ISIS-SMNRx from Biogen and Isis Read More »
